Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis - Wikidata - awgldk - TriplyDB

Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis

Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis

http://www.wikidata.org/entity/Q33796005

about

Antileishmanial activity of a mixture of Tridax procumbens and Allium sativum in mice Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response Identification of proteins in promastigote and amastigote-like Leishmania using an immunoproteomic approach Leishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasis Immunoinformatics Features Linked to Leishmania Vaccine Development: Data Integration of Experimental and In Silico Studies.Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis In vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasis Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications.Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice.Leishmaniasis Vaccine: Where are We Today?A canine model of experimental infection with Leishmania (L.) mexicana Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches Vaccines to prevent leishmaniasis.Vaccination with Leishmania infantum acidic ribosomal P0 but not with nucleosomal histones proteins controls Leishmania infantum infection in hamsters Pioneering neglected disease research in southern Mexico at the "Dr. Hideyo Noguchi" regional research center.Development of Vaccines against Visceral Leishmaniasis From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.The development and clinical evaluation of second-generation leishmaniasis vaccines.Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant DNA vaccines against tropical parasitic diseases.HisAK70: progress towards a vaccine against different forms of leishmaniosis.Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice.DNA Vaccines against Protozoan Parasites: Advances and Challenges Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis.Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas.Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection.Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis.Vaccine Development Against Leishmania donovani.F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis.Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis.Cross-protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis.3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine.Immunogenicity and protective efficacy of DNA vaccine against visceral leishmaniasis in BALB/c mice Segregated growth kinetics of Escherichia coli DH5α-NH36 in exponential-fed perfusion culture for pDNA vaccine production.

P2860

Q24568370-5790DF6A-4365-4DF6-8052-74B5CA4C2DA8 Q28476049-3020A91C-18E0-4722-8AB6-03777A6AC2F7 Q28478933-4F13B227-37B0-46F4-8295-6E8A9B5FE3CB Q28483976-4FC01E96-37B4-47FD-85B3-6C5D488D0B18 Q31162563-432891BA-3A55-453D-A828-12663DC40F0E Q33463435-CD11CEFE-9302-4787-A475-E0B609D8EEF3 Q33559668-D2E335CD-CEA6-47AF-AD38-ADCA8BF18F32 Q33579979-064EC3D1-DBAE-4749-BEEF-0A07A150C01F Q33659753-CD935C58-5AAC-4E85-B0B1-A781431FEC54 Q33737949-41869AE8-0B61-4998-A07A-F60D8F710784 Q33817531-AC2D4754-D704-47B3-8874-39FB5595C743 Q33818084-28B9DD03-6B2E-484F-BE0A-C02655C16088 Q33929859-9B772DFB-15CA-41D0-BE26-CEC3E6718B90 Q34067596-4072B2AB-2ED8-4730-94FB-0C6BDCAAFCA0 Q34076804-6AAFF23F-123D-4CF6-9E9E-2CB77241888E Q34511559-6B865907-3DAE-4E39-BBE5-655F05A9D1AD Q35038313-A7F20F16-A570-40CA-98D4-466FC3B0AC57 Q35054180-1A6E9215-F049-47AE-8726-4A6348040534 Q35207606-B52FCCBC-CE62-4FDF-9DE6-84225476C40D Q35809113-74CAA7D0-2A6B-416A-B593-A82609B035C6 Q35986733-C9BCB54F-FBD0-4A20-A7AD-8839CD338F91 Q36141819-366DCCBB-7459-48BE-BCC7-A5F8BFFA8E61 Q36238733-700C3324-2098-45DB-8699-DCAC042C3902 Q36361604-48D9502D-9144-4058-90F9-E54B20DE00B1 Q36625975-C6A00BBB-EF33-4F61-B8EF-10F3E2A17772 Q36915067-4A3AE1DD-C9FD-4C69-8766-4E021F64113F Q36958635-951F197E-435C-4EF6-AAAE-8F290521EDE6 Q37135480-FE829611-9E5A-4522-95C7-A6254C4CA214 Q37147622-DA16C873-623E-4EBE-906E-F4B01F66ADA1 Q37223654-D6A092DC-8042-4B9A-A15A-62A7AD716F93 Q37229935-BCC06506-E623-4488-A75E-5CAE0F692F47 Q37660825-290B4000-2B86-4F3B-8129-6FA81D5A234B Q37681902-1FDBB603-F2E0-4F7B-B46A-3FF2C83B8A3F Q38012112-A541861C-B370-42CC-9641-495C2CC2CB0C Q38658902-7CF55247-EDCF-49E0-8B39-CB4E357E0EE6 Q38947177-A446070C-D7A8-4DB5-975F-1E9934AE6863 Q39220191-10F42ED8-58D5-46E8-8F0A-9CF2F762F3BB Q39575305-3B407F5D-EDD1-4679-8D66-B0967264E1D5 Q40572422-8FA2E7CC-DDF3-4D1A-8880-453DF043E0BA Q41628326-56BB0B14-01C7-44AC-A3CE-F0C77802BF49

P2860

Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis

http://www.wikidata.org/entity/Q33796005

description

2005 nî lūn-bûn

@nan

2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Cross-protective efficacy of a ...... cutaneous murine leishmaniasis

@ast

Cross-protective efficacy of a ...... cutaneous murine leishmaniasis

@en

type

label

Cross-protective efficacy of a ...... cutaneous murine leishmaniasis

@ast

Cross-protective efficacy of a ...... cutaneous murine leishmaniasis

@en

prefLabel

Cross-protective efficacy of a ...... cutaneous murine leishmaniasis

@ast

Cross-protective efficacy of a ...... cutaneous murine leishmaniasis

@en

P1433

Q33796005-5D1109B2-D809-4475-B354-2E93A97A9FE1

P1476

Q33796005-0507A83E-E516-4E9E-801E-9003BC1066D2

P2093

Q33796005-130ACD02-CF53-408D-B290-5975E69D3AB1

Q33796005-1FFCAA44-9794-488F-8B94-5FF4F7EAFEF0

Q33796005-5BB63AD9-A2F4-4352-AADF-1E4DCBC5612C

Q33796005-63C6E77F-0F0F-4C28-89B5-6F085C52033F

Q33796005-73D15C79-93F7-405C-B559-62128FE57CE0

Q33796005-92194718-43F1-4BB3-961F-666492AC5299

P2860

Q33796005-039746AC-260B-4936-AD18-3D6740194592

Q33796005-0B89DCD9-AA3E-4396-8B73-3D0BE6AC31EF

Q33796005-1900BCA9-A9E7-4828-92D0-6F06B645C403

Q33796005-1A1DD35E-DDE6-48B2-87DF-7AC514D86B52

Q33796005-22B021BD-B9CA-487A-99C2-95899AAFB0D3

Q33796005-22F7B380-FE5E-4B3A-AEB9-CD0406924203

Q33796005-237AD7EC-E96F-4223-9FF0-39948F611537

Q33796005-261064B5-2084-4F51-AFAA-7F3701810475

Q33796005-272A3F10-49B3-4B47-BCC8-7C30CA6F4148

Q33796005-2D11F0FF-F6B3-496D-8C97-0B3F39D57E87

P304

Q33796005-4D8B32D4-68DC-4D47-9A8B-093DAD3B8546

P31

Q33796005-1F280F42-F959-4C91-AA30-1B153FFF7432

P356

Q33796005-F9EA6301-0122-4007-B199-A31135BC083C

P407

Q33796005-0B387A39-C64D-4962-8CF7-7B99FDFF3761

P433

Q33796005-0FC6E7AB-6862-4001-B11F-AD8C998F5EAA

P478

Q33796005-4F5A162E-215A-42DB-AC7C-05D0CA41196B

P50

Q33796005-4CF66BF5-5296-45DA-801B-4D00EEC085E7

Q33796005-5E7E89D1-C27E-4F60-AFFD-FAD7D9E08BB4

Q33796005-C428B22E-24F8-487B-B212-1A78E23A3B23

P577

Q33796005-630BB482-369F-49F8-90EE-EDBAFF72A844

P5875

Q33796005-12BA7990-731E-402F-8CBF-AFEA797B34F3

P698

Q33796005-32F277EA-CA44-4A9E-89D4-A001007E37C7

P932

Q33796005-EBAE8F9C-80E1-42A8-902F-76FFB8B03039

P356

IAI.73.2.812-819.2005

P1433

Infection and Immunity

P1476

Cross-protective efficacy of a ...... cutaneous murine leishmaniasis

@en

P2093

Edilma Paraguai de Souza

http://www.w3.org/2001/XMLSchema#string

Ingrid Aguilar-Be

http://www.w3.org/2001/XMLSchema#string

Maria del Rosario García-Miss

http://www.w3.org/2001/XMLSchema#string

Miguel Rosado-Vallado

http://www.w3.org/2001/XMLSchema#string

Mirza Mut-Martin

http://www.w3.org/2001/XMLSchema#string

Renata da Silva Zardo

http://www.w3.org/2001/XMLSchema#string

P2860

The strange case of Leishmania chagasi

A nonspecific nucleoside hydrolase from Leishmania donovani: implications for purine salvage by the parasite.

DNA-Based immunization with Trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protection against Trypanosoma cruzi infection

Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis

Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice

Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits.

Mechanisms of pathogenesis: differences amongst Leishmania species.

Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate ligands

DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous Leishmaniasis

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

P304

812-819

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.73.2.812-819.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P50

Clarisa Beatriz Palatnik-de-Sousa

Gulnara Patrícia Borja-Cabrera

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8066548

http://www.w3.org/2001/XMLSchema#string

P698

15664920

http://www.w3.org/2001/XMLSchema#string

P932

547025

http://www.w3.org/2001/XMLSchema#string